Trial · NCT03129360

Levetiracetam in Early Psychosis

NCT03129360, Phase 2, Completed, NYU Langone Health; results first posted 2022-11-21

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Levetiracetam in Early Psychosis. Trials, record NCT03129360. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03129360

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Levetiracetam in Early Psychosis
NCT number: NCT03129360
Status: Completed
Phases: Phase 2
Enrollment: 48 participants, actual
Lead sponsor: NYU Langone Health
Conditions: Psychosis, Schizophrenia, Schizo Affective Disorder, Schizophreniform
Interventions: Levetiracetam, Placebo
First posted: 2017-04-26
Last updated: 2022-11-21
Results first posted: 2022-11-21

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Cerebral Blood Flow (CBF)	Baseline, 2 Hours Post-Treatment	CBF will be measured by Arterial Spin Labeling (ASL)

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in Cerebral Blood Flow (CBF)	Baseline, 2 Hours Post-Treatment		mL / (100g * min)	MEAN

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change in Cerebral Blood Flow (CBF)	Levetiracetam 185 mg	-2.21	Standard Deviation 3.2	mL / (100g * min)
Change in Cerebral Blood Flow (CBF)	Levetiracetam 500mg	-3.83	Standard Deviation 2.29	mL / (100g * min)
Change in Cerebral Blood Flow (CBF)	Placebo	-1.29	Standard Deviation 1.66	mL / (100g * min)

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Levetiracetam 185 mg	9
Overall Study	STARTED	Levetiracetam 500mg	8
Overall Study	STARTED	Placebo	8
Overall Study	COMPLETED	Levetiracetam 185 mg	8
Overall Study	COMPLETED	Levetiracetam 500mg	6
Overall Study	COMPLETED	Placebo	7
Overall Study	NOT COMPLETED	Levetiracetam 185 mg	1
Overall Study	NOT COMPLETED	Levetiracetam 500mg	2
Overall Study	NOT COMPLETED	Placebo	1

Source ClinicalTrials.gov

Adverse events18

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Memory Problems	Nervous system disorders	Levetiracetam 185 mg	0	9
other	Memory Problems	Nervous system disorders	Levetiracetam 500mg	1	8
other	Memory Problems	Nervous system disorders	Placebo	0	8
other	Sedation/Drowsiness	Nervous system disorders	Levetiracetam 185 mg	1	9
other	Sedation/Drowsiness	Nervous system disorders	Levetiracetam 500mg	1	8
other	Sedation/Drowsiness	Nervous system disorders	Placebo	0	8
other	Hallucinations	Nervous system disorders	Levetiracetam 185 mg	0	9
other	Hallucinations	Nervous system disorders	Levetiracetam 500mg	0	8
other	Hallucinations	Nervous system disorders	Placebo	1	8
other	Dizziness	General disorders	Levetiracetam 185 mg	0	9

1 to 10 of 18Source ClinicalTrials.gov

See all 18 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Levetiracetam 185 mg	0	9
Total, all-cause mortality	Levetiracetam 500mg	0	8
Total, all-cause mortality	Placebo	0	8
Total, other adverse events	Levetiracetam 185 mg	2	9
Total, other adverse events	Levetiracetam 500mg	4	8
Total, other adverse events	Placebo	1	8
Total, serious adverse events	Levetiracetam 185 mg	0	9
Total, serious adverse events	Levetiracetam 500mg	0	8
Total, serious adverse events	Placebo	0	8

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03129360

GET https://conductscience.org/api/trials/v1/NCT03129360/registered

API reference For AI assistants